Key Takeaways California’s CalRx insulin pens will launch Jan. 1 at $11 each, or $55 for a five-packThe state has invested $100 million to lower insulin costsThe effort could save patients $2,000 to ...

Eli Lilly has partnered with Cipla to market its weight-loss drug tirzepatide in India under the brand name Yurpeak, offering weekly injectable doses to expand access to obesity care.

Gov. Gavin Newsom says California will begin selling affordable insulin under its own label on Jan. 1, nearly three years ...

IF you’ve ever searched for weight loss tips online, you will know the deep rabbit hole that awaits. But now, social media ...

Dubbed the 'world's biggest raid', it was also the first illicit production facility for weight loss medicine discovered in ...

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

"GLP-1RA microdosing trend continues despite “anecdotal evidence”" was originally created and published by Pharmaceutical ...

The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo ...

We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving ...

Starting in the new year, insulin pens will be available at a recommended price of $ ... As a comparison, the equivalent of a five-pack of Eli Lilly’s Rezvoglar sells to pharmacies for more than $88, ...

Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.